Skip to main content

Table 1 Characteristics of included studies

From: Induction therapy with mesenchymal stromal cells in kidney transplantation: a meta-analysis

Author Year Design of the study Population characteristics Cases Follow up (month) Interventions MSCs types MSCs sources MSCs doses and procedure Maintenance immunosuppressants
Treatment group Control group Treatment group Control group Treatment group Control group
Erpicum [20] 2018 Single-centre, nonrandomized, controlled study Deceased donor kidney transplant recipients 10 10 12 months MSC + Anti–IL-2 receptor antibody (D0 + D4) Anti–IL-2 receptor antibody (D0 + D4) Allogeneic BM One intravenous injection (1.5 × 106–3 × 106 cells/kg D3 ± 2) Steroids, MMF, CNIs Steroids, MMF, CNIs
Tan [21] 2012 Single-centre, prospective RCT Living-related donor kidney transplant recipients 52 51 12 months MSCs Anti–IL-2 receptor antibody (20 mg D0 + D4) Autologous BM Two intravenous injections (1–2 × 106 cells/kg before surgery and D14) Steroids, MMF, 80% of the standard of CNIs Steroids, MMF, CNIs
Sun [22] 2018 Multi-center prospective RCT Deceased donor kidney transplant recipients 21 21 12 months MSC + ATG (50 mg/day D0–2) ATG (50 mg/day D0–2) Allogeneic UC Two intravenous injections (2 × 106 cells/kg 30 mins before surgery, 5 × 106 cells during surgery) Steroids, MMF, CNIs Steroids, MMF, CNIs
Pan [23] 2016 Single-centre, prospective, nonrandomized pilot study Living-related donor kidney transplant recipients 16 16 24 months MSCs+Cytoxan (200 mg/day D0–3) Cytoxan (200 mg/day D0–3) Allogeneic BM Two injections (5 × 106 cells through renal allograft artery during surgery, 2 × 106 cells/kg intravenously D30) Steroids, MMF, 60% of the standard of CNIs Steroids, MMF, CNIs
  1. RCT Randomized control trial, MSCs Mesenchymal stromal cells, ATG Antithymocyte globulin, BM Bone marrow, UC Umbilical cord, CNIs Calcineurin inhibitors, MMF Mycophenolate mofetil